Details for New Drug Application (NDA): 012265
✉ Email this page to a colleague
NDA 012265 describes NAQUIVAL, which is a drug marketed by Schering and is included in one NDA. Additional details are available on the NAQUIVAL profile page.
The generic ingredient in NAQUIVAL is reserpine; trichlormethiazide. There are nineteen drug master file entries for this compound. Additional details are available on the reserpine; trichlormethiazide profile page.
The generic ingredient in NAQUIVAL is reserpine; trichlormethiazide. There are nineteen drug master file entries for this compound. Additional details are available on the reserpine; trichlormethiazide profile page.
Summary for 012265
| Tradename: | NAQUIVAL |
| Applicant: | Schering |
| Ingredient: | reserpine; trichlormethiazide |
| Patents: | 0 |
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET;ORAL | Strength | 2MG | ||||
| Approval Date: | Approved Prior to Jan 1, 1982 | TE: | RLD: | No | |||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET;ORAL | Strength | 4MG | ||||
| Approval Date: | Approved Prior to Jan 1, 1982 | TE: | RLD: | No | |||||
Profile for product number 003
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET;ORAL | Strength | 0.1MG;4MG | ||||
| Approval Date: | Approved Prior to Jan 1, 1982 | TE: | RLD: | No | |||||
Complete Access Available with Subscription
